Biohaven Pharmaceutical Hld

Biohaven Ltd. operates as a biopharmaceutical company that focuses on neurological and neuropsychiatric diseases. Its portfolio includes treatments for medical needs including focal epilepsy, obsessive compulsive disorder, spinocerebellar ataxia and spinal muscular atrophy. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Pfizer

Pfizer Inc's $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it may usher in more buyouts as cash-flush drugmakers look to snap up beaten-down smaller biotechs.

Pfizer's $11.6 billion Biohaven buy could spark more biotech deals

Wilmington, Delaware--(Newsfile Corp. - May 11, 2022) - Rigrodsky Law, P.A. is investigating Biohaven Pharmaceutical Holding Co. Ltd. ("Biohaven") (NYSE: BHVN) regarding possible breaches of fiduciary duties and other violations of law related to Biohaven's agreement to be acquired by Pfizer Inc. (NYSE: PFE). Under the terms of the agreement, Biohaven's shareholders will receive $148.50 in cash for each share of Biohaven common stock they own.To learn more about this investigation and your rights, visit:...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Biohaven Pharmaceutical Holding Co. Ltd.

"We have to bring the modern day, novel therapies to those patients, and Pfizer really is the best company to build upon our work," Coric said.

Pfizer deal will help expand reach of migraine pill Nurtec, Biohaven CEO says

NEW YORK , May 10, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") (NYSE: BHVN) in connection with the proposed acquisition of the Company by Pfizer Inc. ("Pfizer") (NYSE: PFE).

SHAREHOLDER ALERT: Weiss Law Investigates Biohaven Pharmaceutical Holding Company Ltd.

BHVN stock is enjoying a nearly 70% jump today after Biohaven Pharmaceutical announced it has been acquired by Pfizer. The post Why Is Biohaven Pharmaceutical (BHVN) Stock Up Today?

Why Is Biohaven Pharmaceutical (BHVN) Stock Up Today?

An industry titan wants to buy the biotech for a whopping $11.6 billion.

Why Biohaven Pharmaceutical Stock Soared Today

In a previous discussion on April 28, I speculated that Biogen Inc. ( BIIB , Financial) might be one of the companies interested in acquiring Biohaven Pharmaceutical Holding Co. Ltd. ( BHVN , Financial), a New Haven, Connecticut-based biopharma.

After Biohaven, Pfizer Likely to Remain on Acquisition Binge

Appian

Find out how the rest of the markets are behaving.

2 Extraordinary Events Sent These 2 Stocks Soaring Tuesday

Pfizer Inc. agreed to buy the rest of Biohaven Pharmaceutical Holding Co. for about $11.6 billion, deploying its pile of cash earned from Covid-19 sales to acquire a new migraine drug.

Pfizer to buy rest of Biohaven for $11.6B

Pfizer Inc (NYSE:PFE) has agreed a US$11.6bn offer for Biohaven Pharmaceutical Holding Co (NYSE:BHVN), which has reignited talk that more mergers and acquisitions (M&A) could be around the corner in the biotech sector.  The takeover has been struck for US$148.5 of cash per share, a 78% premium to the last closing price.

Pfizer splashes $11.6bn of vaccine cash on Biohaven Pharmaceutical Holding

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -17.86% and 70.40%, respectively, for the quarter ended March 2022.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q1 Loss, Tops Revenue Estimates

Pfizer Inc (NYSE: PFE) will acquire Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) for $148.50 per share, equivalent to $11.6 billion.  Pfizer will also make payments at closing to settle Biohaven's third-party debt and for the redemption of all.

Pfizer Acquires This Migraine Drug Maker For $11B: What Investors Need To Know

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) to Pfizer Inc. for $148.50 per share in cash is fair to Biohaven shareholders. Biohaven common shareholders, including Pfizer, will also receive 0.5 of a share of New Biohaven, a new publicly traded company that will retain Biohaven's non-CGRP development stage pipeline compounds, per Biohaven common share. Halper Sadeh encourag

BHVN Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Biohaven Pharmaceutical Holding Company Ltd. Is Fair to Shareholders

Shares of Biohaven soared following the announcement.

Pfizer to Buy Biohaven Pharmaceuticals for $11.6 Billion

(Reuters) -Pfizer Inc said on Tuesday it will buy migraine drug maker Biohaven Pharmaceutical Holding Company Ltd for about $11.6 billion in cash.

Pfizer to buy Biohaven Pharmaceutical in $11.6 billion deal

Pfizer Inc. PFE, -0.82% said Tuesday it has entered a definitive agreement to acquire Biohaven Pharmaceutical Holding Company Ltd. BHVN, -7.88% for $11.6 billion in cash.

Pfizer to acquire Biohaven Pharma for $11.6 billion in cash sending Biohaven shares up 74% premarket

Pfizer Inc. (NYSE: PFE) announced it is buying Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) in a deal valued at $11.6 billion in cash.

Why Pfizer (PFE) Is Buying Biohaven Pharmaceutical (BHVN) For $11.6 Billion In Cash

Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven Record reported revenues of $319 million NURTEC® ODT (rimegepant) TRx volumes grew 8% versus the fourth quarter and net product revenue was $124 million for the first quarter of 2022 Net product sales guidance of $825 - $900 million provided for 2022 Received EU approval from the European Commission ("EC") for rimegepant 75 mg for the acute and preventive treatment of migraine; EC marketing authorization valid in all 27 member countries of the European Union Expanded payer coverage for NURTEC ODT, extending coverage to 96 percent of total commercial lives and approximately 263 million people in all payer channels Featured 13 abstracts, including two oral presentations, at the 2022 American Academy of Neurology Annual Meeting, notably highlighting NURTEC ODT's clinical utility as demonstrated by a reduction in opioid prescriptions filled and medication overuse headache following treatment U.S. Food and Drug Administration ("FDA") approved NURTEC ODT label amendment to include clinical lactation data Initiated enrollment in two new Phase 2/3 clinical trials assessing the safety and efficacy of NURTEC ODT 75 mg in patients with sinusitis and temporomandibular disorder NEW HAVEN, Conn.

Biohaven Reports First Quarter 2022 Financial Results and Reports Recent Business Developments

NEW YORK & NEW HAVEN, CONN.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Biohaven not alread

Pfizer to Acquire Biohaven Pharmaceuticals

NEW HAVEN, Conn. , May 9, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven to Discuss First Quarter 2022 Financial Results and Recent Business Developments on May 11, 2022

Biohaven Pharmaceutical (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Biohaven Pharmaceutical (BHVN) This Earnings Season?

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Biohaven Pharmaceutical Holding Company Ltd. ( BHVN , Financial) recently shrugged off concerns about its lack of transparency on sales of its only commercial product after investors punished the company's shares.

Biohaven Shares Drop Over Uncertainty About Nurtec Sales

NEW YORK & NEW HAVEN, Conn.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorization for VYDURA® (rimegepant), a calcitonin gene-related peptide (CGRP) receptor antagonist for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have at least four migraine attacks per month. VYDURA®, an orally disintegrating

Pfizer and Biohaven's VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine

More than 25% of patients reported being severely or very severely impacted by their migraine attacks Study showed higher levels of migraine-related disability were associated with increased HCRU costs in primary care and specialty settings among adults with episodic migraine Data suggests that assessment of disability in people with migraine may support prescribing of cost-effective interventions, particularly among those with severe disability NEW HAVEN, Conn., April 14, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Real-World Study Highlights Increased Healthcare Utilization Among Americans with Episodic Migraine having Higher Levels of Migraine-Related Disability

News for Biohaven Pharmaceutical Hld Stock (BHVN)